“…Several large international liver disease societies recommended changing the nosology of fatty liver disease to steatotic liver disease (SLD), with subcategories of metabolic dysfunction–associated steatotic liver disease (MASLD), alcohol liver disease (ALD), and the combination of MASLD and ALD as “MetALD.” The impact of this shift will need to be evaluated in subsequent studies and reflected in updated guidelines. Upcoming data from larger RCTs of GLP1RAs, GIPRAs/GLP1RAs, and sodium-glucose cotransporter 2 inhibitors should help clarify their direct effects on NASH.…”